Author + information
- Received September 6, 2018
- Accepted September 20, 2018
- Published online January 7, 2019.
- Sean M. Davidson, PhDa,∗∗ (, )@UCL,
- Péter Ferdinandy, PhDb,c,∗,
- Ioanna Andreadou, PhDd,
- Hans Erik Bøtker, MD, PhDe,
- Gerd Heusch, MD, PhDf,
- Borja Ibáñez, MD, PhDg,h,i,
- Michel Ovize, MD, PhDj,
- Rainer Schulz, MD, PhDk,
- Derek M. Yellon, PhD, DSca,
- Derek J. Hausenloy, MD, PhDa,l,m,n,o,†,
- David Garcia-Dorado, MD, PhDi,p,q,∗∗,† (, )@VHIR,
- on behalf of the European Union CARDIOPROTECTION COST Action (CA16225)
- aThe Hatter Cardiovascular Institute, University College London, London, United Kingdom
- bDepartment of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary
- cPharmahungary Group, Szeged, Hungary
- dLaboratory of Pharmacology, Faculty of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece
- eDepartment of Cardiology, Aarhus University Hospital Skejby, Aarhus N, Denmark
- fInstitute for Pathophysiology, West German Heart and Vascular Center, University of Essen Medical School, Essen, Germany
- gCentro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain
- hCIBER de Enfermedades CardioVasculares, Madrid, Spain
- iIIS-Fundación Jiménez Díaz University Hospital, Madrid, Spain
- jINSERM U1060, CarMeN Laboratory, Université de Lyon and Explorations Fonctionnelles Cardiovasculaires, Hôpital Louis Pradel, Hospices Civils de Lyon, Lyon, France
- kInstitute of Physiology, Justus-Liebig University Giessen, Giessen, Germany
- lCardiovascular & Metabolic Disorders Program, Duke-National University of Singapore Medical School, Singapore
- mNational Heart Research Institute Singapore, National Heart Centre, Singapore
- nYong Loo Lin School of Medicine, National University Singapore, Singapore
- oTecnologico de Monterrey, Escuela de Ingenieria y Ciencias, Centro de Biotecnologia-FEMSA, Nuevo Leon, México
- pDepartment of Cardiology, Vascular Biology and Metabolism Area, Vall d’Hebron University Hospital and Research Institute (VHIR), Barcelona, Spain
- qUniversitat Autónoma de Barcelona, Barcelona, Spain
- ↵∗Address for correspondence:
Dr. Sean M. Davidson, The Hatter Cardiovascular Institute, University College London, 67 Chenies Mews, London WC1E 6HX, United Kingdom.
- ↵∗∗Dr. David Garcia-Dorado, Servicio de Cardiología, Hospital Universitari Vall d’Hebron, Passeig Vall d’Hebron, 119-129, 08035, Barcelona, Spain.
Many treatments have been identified that confer robust cardioprotection in experimental animal models of acute ischemia and reperfusion injury. However, translation of these cardioprotective therapies into the clinical setting of acute myocardial infarction (AMI) for patient benefit has been disappointing. One important reason might be that AMI is multifactorial, causing cardiomyocyte death via multiple mechanisms, as well as affecting other cell types, including platelets, fibroblasts, endothelial and smooth muscle cells, and immune cells. Many cardioprotective strategies act through common end-effectors and may be suboptimal in patients with comorbidities. In this regard, emerging data suggest that optimal cardioprotection may require the combination of additive or synergistic multitarget therapies. This review will present an overview of the state of cardioprotection today and provide a roadmap for how we might progress towards successful clinical use of cardioprotective therapies following AMI, focusing on the rational combination of judiciously selected, multitarget therapies. This paper emerged as part of the discussions of the European Union (EU)-CARDIOPROTECTION Cooperation in Science and Technology (COST) Action, CA16225.
↵∗ Drs. Davidson and Ferdinandy are joint first authors.
↵† Drs. Hausenloy and Garcia-Dorado are joint senior authors.
This paper is based upon work FROM COST ACTION EU-CARDIOPROTECTION CA16225 supported by COST (European Cooperation in Science and Technology). Dr. Davidson was supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. Dr. Ferdinandy has been supported by the the National Research, Development and Innovation Office of Hungary (NVKP_16-1-2016-0017; OTKA KH 125570; and OTKA 115378) and by the Higher Education Institutional Excellence Programme of the Ministry of Human Capacities in Hungary, within the framework of the Therapeutic Development thematic programme of the Semmelweis University. Dr. Bøtker was supported by The Danish Council for Strategic Research (11-108354), Novo Nordisk Foundation (Conditioning Based Intervention Strategies–ConBis), and Trygfonden. Dr. Heusch was supported by the German Research Foundation (SFB 1116, B 08). Dr. Ovize has been supported by the OPeRa (ANR-10-IBHU-0004 OPeRa) and the RHU MARVELOUS (ANR-16-RHUS-0009) programs. Dr. Schulz was funded by the German Research Foundation SFB/CRC 1213/B05. Dr. Hausenloy was supported by the British Heart Foundation (FS/10/039/28270), the National Institute for Health Research University College London Hospitals Biomedical Research Centre, Duke-National University Singapore Medical School, Singapore Ministry of Health’s National Medical Research Council under its Clinician Scientist-Senior Investigator scheme (NMRC/CSA-SI/0011/2017) and Collaborative Centre Grant scheme (NMRC/CGAug16C006), and the Singapore Ministry of Education Academic Research Fund Tier 2 (MOE2016-T2-2-021). Dr. Garcia-Dorado was supported by the Instituto de Salud Carlos III, CIBERCV-Instituto de Salud Carlos III, Spain (grant CB16/11/00479 to DGD, cofunded with European Regional Development Fund-FEDER contribution), and grants PIE/2013-00047 and PI 17/1397. Dr. Ferdinandy is the founder and CEO of Pharmahungary Group, a group of R&D companies. Dr. Bøtker is a shareholder in CellAegis Inc. Dr. Yellon has served on advisory boards for Novo Nordisk and MSD. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Listen to this manuscript's audio summary by Editor-in-Chief Dr. Valentin Fuster on JACC.org.
- Received September 6, 2018.
- Accepted September 20, 2018.
- 2019 The Authors